Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

Purpose: To describe the phase 1 and population pharmacokinetic investigations that support dosing recommendations for elbasvir/grazoprevir (EBR/GZR) in hepatitis C virus-infected people with advanced chronic kidney disease. Methods: This was an open-label, two-part, multiple-dose trial (MK-5172 PN0...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 75; no. 5; pp. 665 - 676
Main Authors:	Caro, Luzelena, Wenning, Larissa, Feng, Hwa-Ping, Guo, Zifang, Du, Lihong, Bhagunde, Pratik, Fandozzi, Christine, Panebianco, Deborah, Marshall, William L., Butterton, Joan R., Iwamoto, Marian, Yeh, Wendy W.
Format:	clinical trial research tables/charts Journal Article
Published:	Springer Nature May2019
Online Access:	View this record in EBSCOhost